Drug
Aln App
Aln App: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-APP NCT06393712 | Phase 2 | Cerebral Amyloid Angiopathy |
| ALN-APP NCT05231785 | Phase 1 | Early-Onset Alzheimer Disease |
Latest
No recent events.
Follow Aln App on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.